If your cells fail a required quality test before treatment, the affected batch should not proceed through routine release. The clinic and cell-processing laboratory need to investigate the result and document whether the batch can be used. A confirmed failure can mean a delay, a replacement batch, another collection, or cancellation. Ask for the batch decision and your revised treatment plan in writing.
A pending test is not the same as a failed test. For some short-lived investigational cell products, final sterility results can arrive after administration under a specified testing and follow-up plan. FDA guidance addresses this situation separately from a known failure.Download

This guide is general information, not personal medical advice. The laboratory’s quality team handles batch release; your treating doctor explains the medical consequences and next steps. Requirements depend on the product, treatment setting, and country.
What Was Being Tested
Ask which test failed and for the written acceptance criterion: the result or range the product must meet. Cell-product testing can cover identity, purity, potency, viability, cell number, and microbial safety. The exact panel and limits depend on the product and its development stage; the FDA’s somatic-cell guidance is a US investigational framework, not a universal checklist for every clinic.Download
| Check | What it asks |
|---|---|
| Identity | Are these the expected cells? |
| Cell count and viability | How many living cells are present, and how were they measured? |
| Purity | Are unwanted cells or leftover processing materials within limits? |
| Potency | Does the batch meet the specified test for its relevant biological activity? This is not a guarantee that treatment will work for you. |
| Sterility | Do tests detect bacterial or fungal contamination? |
| Mycoplasma | Does a dedicated test detect these wall-less bacteria, which ordinary microscopy cannot see? |
| Endotoxin | Are bacterial toxin levels within your product’s own limit? There is no single universal cutoff. |
| Appearance and container | Does the product look normal, and is the container intact? |
| Release decision | Does the batch meet its applicable release criteria, and who authorized its use? |
Read a numerical result beside its limit, units, method, and sample date. For a qualitative result such as microbial growth, ask what was detected and how the finding is being investigated.
When a Result Becomes a Failure
A result outside the written acceptance criteria is called out-of-specification, or OOS. It requires investigation; it should not be dismissed simply because a repeat test passes. FDA’s OOS guidance describes an initial laboratory assessment followed, when needed, by a broader investigation of manufacturing and other possible causes.Download
That document applies to chemistry-based testing of drugs regulated by FDA’s drug center. It illustrates investigation principles here; it does not replace cell-product-specific release rules or Japanese requirements.Download
| Investigation result | What it means for you |
|---|---|
| Invalidated by a proven laboratory cause | The original result may be invalidated on documented scientific grounds. That alone does not establish that every other release requirement has been met. |
| Confirmed failure | The batch does not meet its specification. Under the cited FDA drug guidance, confirmed OOS should result in rejection and proper disposition; ask how your product’s applicable rules are being followed. |
| Inconclusive | The original OOS result must receive full consideration. FDA’s drug guidance allows a quality-unit release decision in some inconclusive cases after comprehensive assessment; neither automatic acceptance nor automatic rejection is justified by the word “inconclusive” alone. |
A passing retest does not, by itself, erase the first failure. FDA calls repeated testing solely to obtain a passing result “testing into compliance” and describes it as unscientific and objectionable. Retesting needs a scientific rationale and a documented investigation.Download
What Happens to the Failed Batch
Ask the clinic to confirm that the affected batch is on hold, clearly identified, and protected from unintended use while the decision is pending. Request its batch identifier, investigation outcome, and final disposition: what ultimately happened to the material. Rejection and physical disposal are different steps; do not assume the cells were already destroyed.
Under FDA’s drug guidance, a confirmed batch failure also requires investigation of other batches or products potentially associated with that failure.Download Before accepting a replacement, ask whether the same problem could affect it and what corrective action has been taken.
Why Contamination Changes the Decision
Contaminated cells can cause serious infections. In a US outbreak reported by CDC in 2018, 12 patients developed infections after receiving unapproved cord blood-derived products for uses other than blood or immune-system reconstitution. All were hospitalized; no deaths had been reported as of 14 December 2018. Bacteria in unopened vials indicated contamination before distribution.Mm6750a5.htm This was one outbreak, not an overall cell-therapy failure rate.
Appearance alone cannot establish safety. UNC’s tissue-culture guidance notes that mycoplasma can reach 10 million to 100 million organisms per milliliter without being visible under ordinary microscopy. Specific testing is needed, and routine culture antibiotics are not a reliable safeguard.Mycoplasmacontam These are laboratory observations, not patient-specific acceptance limits.
What Happens to Your Treatment
Ask your doctor which of these options is medically appropriate. A failed batch does not, by itself, show that every future batch will fail or explain the underlying cause.
Repeat Collection
If the cells came from your own body, ask whether another collection is necessary or whether suitable stored starting material is available. Do not assume either option is possible. Request a revised schedule for collection if needed, processing, testing, and treatment, and ask whether the delay is safe for you.
Cancellation
Your doctor may recommend cancellation rather than another attempt. Ask what care continues in the meantime and which alternatives are appropriate; do not stop other treatment on your own.
A Different Route
Donor cells are not an automatic swap for your own. Products made from your cells and products made from donor cells differ in source, processing, testing, evidence, and risks, and each needs its own consent talk. Treat a switch as a separate medical decision.
If the Result Arrives After Treatment
FDA’s somatic-cell IND guidance describes some short-lived investigational products being released using specified interim sterility evidence while final cultures continue for the full 14-day test. It calls for a plan to manage a positive result after administration, including patient evaluation and investigation of the failure.Download This is not permission to ignore a known contamination result, nor a rule that every cell treatment requires the same waiting period.
If your clinic reports a positive result after treatment, contact your treating doctor immediately for assessment and follow-up instructions. Before any procedure, ask which results will still be pending, who will contact you, and how you can reach the clinical team after returning home.
What Happens to Costs and Paperwork
After a failure, settle these in writing before you agree to anything:
- Who pays for the repeat collection, processing, and testing?
- Are any fees refunded or credited if treatment is cancelled?
- Does the consent form cover re-collection and the possibility of batch failure?
- Will you receive the investigation summary, the failed result with its acceptance criterion, and the final disposition record?
- If you travel for care, who covers the changed flights, stay, and time off?
For a practical example, suppose the clinic phones to say, “The first test failed, but the repeat passed.” Ask: “Which test and batch? What explains the first result? Who authorized release, and can I have the written conclusion?” This is a suggested conversation, not a report of a patient case. Request dated written confirmation before changing travel or treatment arrangements.
Keep the result, its acceptance criterion, the investigation summary, the batch decision, and your consent documents together. Bring these records to any second-opinion appointment.
What This Means in Japan
A filed treatment plan under Japan’s Act on the Safety of Regenerative Medicine, with its committee-review framework, is not the same thing as approval of a regenerative medical product.Index PMDA publishes approved-product information and review reports through a separate product pathway.0003 A plan filing or study registration does not establish that treatment will work for you.
Ask which regulatory framework applies to your treatment, and request the corresponding quality and incident-reporting procedures. A plan number or product listing is not evidence that your individual batch passed its tests.
What to Ask Next
Bring these questions to your appointment:
- Which exact test failed, against which acceptance criterion, and on which sample and date?
- Was the result confirmed, invalidated by a proven laboratory error, or left inconclusive — and where is that documented?
- Who made the release decision, and can I see it in writing?
- Was the batch quarantined, rejected, or disposed of — and what do the records say?
- Do I need another collection, and is repeating it medically appropriate for me?
- If a result arrives after my procedure, who tells me, and how quickly?
Bottom Line
A failed quality test calls for a documented investigation, not reassurance based on a passing retest alone. Before proceeding, get the batch decision, the medical plan, and the financial arrangements in writing. If the clinic cannot explain the result and its response, seek an independent medical opinion before agreeing to another procedure.
Questions about a failed batch or a repeat collection?
Ask the support team about obtaining your records and arranging questions for your treating doctor.
Contact the support teamGeneral information only — your doctor decides on care.
References
- FDA, Content and Review of Chemistry, Manufacturing, and Control Information for Human Somatic Cell Therapy INDs (April 2008), Sections IV and V
- FDA, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production, Guidance for Industry (May 2022), Sections III–V
- CDC, Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood-Derived Stem Cell Products, United States, 2018 (MMWR 67(50):1397-1399)
- University of North Carolina Lineberger Comprehensive Cancer Center, Tissue Culture Facility: Mycoplasma contamination guidance
- MHLW, Regenerative and Cell Medicine and Gene Therapy (Act on the Safety of Regenerative Medicine framework)
- PMDA, Regenerative Medical Products (approved information)




